Equities

Shanghai Yizhong Pharmaceutical Co Ltd

688091:SHH

Shanghai Yizhong Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)27.16
  • Today's Change0.90 / 3.43%
  • Shares traded2.93m
  • 1 Year change-35.71%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2401,128953
Total Receivables, Net1434213
Total Inventory281712
Prepaid expenses0.931112
Other current assets, total0.531.763.36
Total current assets1,4131,200994
Property, plant & equipment, net12212285
Goodwill, net------
Intangibles, net8.588.799.01
Long term investments2120106
Note receivable - long term------
Other long term assets1.371.371.42
Total assets1,5731,3551,201
LIABILITIES
Accounts payable38221.12
Accrued expenses7.586.081.62
Notes payable/short-term debt44017
Current portion long-term debt/capital leases------
Other current liabilities, total152.251.61
Total current liabilities1043021
Total long term debt000
Total debt44017
Deferred income tax3.073.260.79
Minority interest------
Other liabilities, total1.472.293.13
Total liabilities1093525
SHAREHOLDERS EQUITY
Common stock158144106
Additional paid-in capital1,0721,0591,096
Retained earnings (accumulated deficit)235116(27)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,4651,3191,176
Total liabilities & shareholders' equity1,5731,3551,201
Total common shares outstanding206206206
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.